Cti Biopharma Corp Stock
Your prediction
Pros and Cons of Cti Biopharma Corp in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cti Biopharma Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cti Biopharma Corp | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | 0.000% | 2.362% | -2.256% | -17.197% | -21.687% | -52.727% | -82.667% |
| Celldex Therapeutics | 0.520% | 1.587% | -12.727% | -11.111% | -12.727% | -50.920% | -8.222% |
| Achieve Life Sciences Inc. | -3.600% | 1.603% | -26.321% | 8.736% | -5.811% | -30.216% | -71.895% |
Comments
CTI BioPharma Corp. (NASDAQ: CTIC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
Show more
Ratings data for CTIC provided by MarketBeat
CTI BioPharma Corp. (NASDAQ: CTIC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
Show more
Ratings data for CTIC provided by MarketBeat
